Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LRRC52 antisense RNA 1 (LRRC52-AS1)
- Target
- LRRC52-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
LRRC52 antisense RNA 1 (LRRC52-AS1) is a long non-coding RNA (lncRNA) transcribed in the antisense direction relative to the LRRC52 gene, located on chromosome 1 (NCBI 400794, ENSG00000237463)[4][7]. It does not encode a protein and is classified as an antisense RNA that likely regulates gene expression through various mechanisms typical of lncRNAs, such as transcriptional interference or modulation of chromatin structure[3]. Recent research has identified LRRC52-AS1 as significantly upregulated in papillary thyroid cancer (PTC), where it is associated with disease progression and regulates cancer cell migration and invasion[2]. Its expression in fine needle aspiration (FNA) samples is a promising biomarker to differentiate malignant from benign thyroid nodules, suggesting diagnostic utility in clinical settings for thyroid cancer[2]. However, there is currently limited information about drugs directly targeting LRRC52-AS1, and it is not considered a conventional therapeutic target like enzymes, receptors, or ion channels.
- Other names
- LRRC52-AS1ENSG00000237463NCBI 400794
02
Biological functions
Regulation of gene expressionRegulation of cell migration and invasion (particularly in papillary thyroid cancer)
03
Disease associations
Cancer, specifically papillary thyroid cancer (PTC)roles in clinical progression and diagnosis of PTC
04
Biomarkers
LRRC52-AS1 expression levels (biomarker for diagnosis and progression in PTC; used to differentiate malignant from benign thyroid nodules)
Beyond the preview
Go deeper on LRRC52 antisense RNA 1 (LRRC52-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LRRC52 antisense RNA 1 (LRRC52-AS1).